EA200700708A1 - Мемантин для лечения расстройств поведения детского возраста - Google Patents

Мемантин для лечения расстройств поведения детского возраста

Info

Publication number
EA200700708A1
EA200700708A1 EA200700708A EA200700708A EA200700708A1 EA 200700708 A1 EA200700708 A1 EA 200700708A1 EA 200700708 A EA200700708 A EA 200700708A EA 200700708 A EA200700708 A EA 200700708A EA 200700708 A1 EA200700708 A1 EA 200700708A1
Authority
EA
Eurasian Patent Office
Prior art keywords
memantine
behavior
children
diseases
treatment
Prior art date
Application number
EA200700708A
Other languages
English (en)
Other versions
EA012036B1 (ru
Inventor
Джеффри Джонас
Прадип К. Банерджи
Сандип Гупта
Аллисон Манн
Ханс-Йорг Мебиус
Original Assignee
Мерц Фарма Гмбх Унд Ко. Кгаа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35445934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200700708(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерц Фарма Гмбх Унд Ко. Кгаа filed Critical Мерц Фарма Гмбх Унд Ко. Кгаа
Publication of EA200700708A1 publication Critical patent/EA200700708A1/ru
Publication of EA012036B1 publication Critical patent/EA012036B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение обеспечивает способ лечения субъектов с диагнозом расстройства поведения детского возраста, таким как расстройства аутистического спектра или гиперактивного расстройства с дефицитом внимания (ADHD) комбинированного типа введением эффективного количества мемантина.
EA200700708A 2004-09-23 2005-09-23 Мемантин для лечения расстройств поведения детского возраста EA012036B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61260004P 2004-09-23 2004-09-23
PCT/US2005/034199 WO2006034465A1 (en) 2004-09-23 2005-09-23 Memantine for the treatment of childhood behavioral disorders

Publications (2)

Publication Number Publication Date
EA200700708A1 true EA200700708A1 (ru) 2007-08-31
EA012036B1 EA012036B1 (ru) 2009-06-30

Family

ID=35445934

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700708A EA012036B1 (ru) 2004-09-23 2005-09-23 Мемантин для лечения расстройств поведения детского возраста

Country Status (16)

Country Link
US (2) US20060079582A1 (ru)
EP (1) EP1799224A1 (ru)
JP (1) JP2008514620A (ru)
KR (1) KR20070046185A (ru)
CN (1) CN101374525A (ru)
AR (1) AR052643A1 (ru)
AU (1) AU2005286672B2 (ru)
BR (1) BRPI0515560A (ru)
CA (1) CA2578953A1 (ru)
EA (1) EA012036B1 (ru)
IL (1) IL182105A0 (ru)
MX (1) MX2007003267A (ru)
NO (1) NO20072035L (ru)
TW (1) TW200626160A (ru)
WO (1) WO2006034465A1 (ru)
ZA (1) ZA200702130B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
EP2170310A4 (en) * 2007-06-29 2010-06-23 Orchid Chemicals & Pharm Ltd FAST-DISSOLVING COMPOSITIONS OF MEMANTINE HYDROCHLORIDE
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
SI2201950T1 (sl) 2008-12-08 2017-05-31 Biocodex Spojine in metode za zdravljenje motenj avtističnega spektra
IT1396556B1 (it) 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
US9242009B2 (en) 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
UA107653U (uk) * 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
KR101424514B1 (ko) * 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
WO2014153180A1 (en) * 2013-03-14 2014-09-25 Michela Gallagher Methods and compositions for improving cognitive function
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6856968B2 (ja) * 2015-05-22 2021-04-14 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 自閉症スペクトラム障害および関連する症候を治療するための方法
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3518975A1 (en) 2016-08-24 2019-08-07 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
JP7277458B2 (ja) * 2017-08-01 2023-05-19 スチュアート エー． リプトン， 神経学的疾患を治療するための方法および組成物
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US11447442B2 (en) 2017-11-22 2022-09-20 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat CNS disorders
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (ru) * 1972-04-20 1973-10-23
HU169986B (ru) * 1972-12-07 1977-03-28
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6326226B1 (en) * 1997-07-15 2001-12-04 Lg. Philips Lcd Co., Ltd. Method of crystallizing an amorphous film
AU765522B2 (en) * 1998-01-13 2003-09-18 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
WO2001041707A2 (en) * 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US20040019118A1 (en) * 2002-07-19 2004-01-29 Khalid Iqbal NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease

Also Published As

Publication number Publication date
AU2005286672A1 (en) 2006-03-30
CA2578953A1 (en) 2006-03-30
EA012036B1 (ru) 2009-06-30
CN101374525A (zh) 2009-02-25
WO2006034465A8 (en) 2006-06-08
AR052643A1 (es) 2007-03-28
BRPI0515560A (pt) 2008-07-29
NO20072035L (no) 2007-06-13
KR20070046185A (ko) 2007-05-02
US20060079582A1 (en) 2006-04-13
EP1799224A1 (en) 2007-06-27
US20100081723A1 (en) 2010-04-01
TW200626160A (en) 2006-08-01
WO2006034465A1 (en) 2006-03-30
MX2007003267A (es) 2007-05-23
ZA200702130B (en) 2008-09-25
JP2008514620A (ja) 2008-05-08
AU2005286672B2 (en) 2009-03-12
IL182105A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
EA200700708A1 (ru) Мемантин для лечения расстройств поведения детского возраста
TW200517114A (en) Methods and reagents for the treatment of immunoinflammatory disorders
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
DE602005020269D1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
UA85559C2 (en) Aminobenzophenone compounds
DE60236206D1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0515884A (pt) métodos de diagnóstico e tratamento de complicações da gravidez
PA8663601A1 (es) Derivados del 1,5-diarilpirol, su preparacion y su aplicacion en terapia
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
EA200701995A1 (ru) Способы уменьшения кальцификации
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
NO20072290L (no) Organiske forbindelser.
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
MY155340A (en) Use of cathepsin c
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU